Cart
0

LAMEA Oncology/Anti-cancer drugs Market by Therapeutic Modalities (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy) and Cancer Types (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Skin Cancer) - Opportunity Analysis and Industry Forecast, 2014 - 2021

Get 20% Free Customization In This Report
LI_16863
Pages: 108
Feb 2016 | 3441 Views
 
Author's : Adnan Malik
Tables: 44
Charts: 47
 

LAMEA Oncology/Anti-cancer Drugs Market Overview

LAMEA Oncology/Anti-cancer Drugs Market is expected to reach $17,072.2 million by 2021, registering a CAGR of 8.6% during the forecast period 2015 - 2021. Oncology drugs are used for the treatment or management of the various cancer types. It eventually helps improve the quality of life for such patients and extends their chances and duration of survival. The biological drugs for oncological therapeutics are based on monoclonal antibodies (mAbs). They are expected to emerge as the most preferred option for treating various cancer types, especially blood cancer (leukaemia). This is because of the observed improvement in patient outcomes and low risks of side effects on the patient’s overall health and wellness.

The rise in incidence and prevalence of various cancer types, new cancer treatments, and the growing importance of biological and targeted drug therapies are certain factors that drive the market growth of LAMEA oncology/anti-cancer drugs at present. In addition, an increase in demand for anti-cancer drugs for the treatment of ageing population, the hike in government funding, and improved post-treatment results for advanced therapeutic modalities are the major factors that boost the market growth. However, the high costs associated with new drug development procedures, coupled with the threat of failure in deriving successful results, and the adverse effects associated with anti-cancer drugs therapies are expected to restrain the growth of the LAMEA market. The high costs incurred to develop anti-drugs leads to lofty pricing structures and restricts the accessibility for low to medium income population. This is a major challenge that is expected to further impede the growth performance of anti-cancer drugs in LAMEA region. However, a focused attempt to commercialize the advanced oncology therapeutics, such as targeted therapies and immunotherapies (biologic therapies), would reduce the negative influence of restraints and fuel the market growth.

The LAMEA oncology drugs market is segmented into therapeutic modalities, types of cancer, and countries. The therapeutic modalities segment is further categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. Patent expiration of the blockbuster anti-cancer drugs such as Herceptin (Patent Expiration: EU-2014; US-2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU-2013; US-2018), and Avastin (Patent Expiration: EU-2018; US-2019), is expected to boost the growth scenario for the cancer biosimilars market by 2021. The biological therapy is observed to be the fastest growing segment at a CAGR of 12.2%, throughout the analysis period, because of its high efficacy and target-specific action. Moreover, the blood cancer drugs market was the largest revenue generating application segment in 2015. This is majorly due to the high costs of these drugs (immunotherapies) and its widespread application for the treatment of blood cancer, which apparently was the cancer type that claimed maximum patient population in the oncological segment.
Based on countries, the LAMEA anti-cancer drugs market is segmented for study into nine countries, namely Brazil, Argentina, Nigeria, South Africa, Iraq, Iran, Algeria, Saudi Arabia, and Egypt. Out of these, Brazil dominates the LAMEA oncology market closely followed by Argentina. This is due to the rise in incidences of cancer, high per capita expenditure, and a higher gross national income (GNI) of Brazil. In addition, LAMEA market is poised to grow at a promising CAGR of 8.6% during the forecast period. This high growth rate is majorly attributed to the increasing awareness among consumers towards the advanced therapies, such as immunotherapy, and an increase in per capita healthcare spending.
The list of leading companies profiled in the report include Amgen Inc., AstraZeneca Plc., Roche Diagnostics, GlaxoSmithKline PLC, Merck & Co., Novartis AG, AbbVie Inc. Sanofi, EIMC United Pharmaceuticals (EUP), and Actavis plc.

LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET KEY BENEFITS:

  • The report provides a quantitative analysis of the current market and estimations through 2014-2021 that assists in the identification of the prevalent market opportunities.

  • The report helps in understanding the strategies adopted by various companies for gaining increased market share in the LAMEA anti-cancer drugs market.

  • The report provides a comprehensive analysis of factors that drive and restrict the growth of the LAMEA oncology drugs market.

  • Market conditions of anti-cancer drugs market across LAMEA region are comprehensively analyzed.

  • Competitive intelligence highlights the business practices followed by leading market players across various geographies.

  • SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.

LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET KEY SEGMENTS:

LAMEA oncology/anti-cancer drugs market is segmented into therapeutic modalities, cancer types and countries.

  • By Therapeutic modalities

    • Chemotherapy

    • Targeted Therapy

    • Immunotherapy (Biologic Therapy)

    • Hormonal Therapy

    • Others

  • By Cancer Types

    • Blood Cancer (Leukaemia)

    • Breast Cancer

    • Gastrointestinal Cancer

    • Respiratory/Lung Cancer

    • Skin Cancer

    • Other Cancers

  • By Countries

    • Brazil

    • Argentina

    • Nigeria

    • South Africa

    • Iraq

    • Iran

    • Algeria

    • Saudi Arabia

    • Egypt

    • Other LAMEA countries

 

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings

3.3.1 Top impacting factors
3.3.2 Top investment pockets
3.3.3 Top winning strategies

3.4 Government regulations

3.4.1 Regulations in Middle East

3.5 Reimbursement scenario

3.5.1 Reimbursement in Middle East

3.6 Drivers

3.6.1 Rising incidence and prevalence of various cancer types
3.6.2 Growing importance of biological and targeted drug therapies
3.6.3 Increasing funding and aid from public and private sector

3.7 Restraints

3.7.1 High cost of drug development and threat of failure
3.7.2 Adverse effects of cancer drug therapy

3.8 Opportunities

3.8.1 Advancement of anti-cancer drugs research
3.8.2 Healthcare and medical awareness

Chapter: 4 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES,2014-2021

4.1 Chemotherapy

4.1.1 Market size and forecast

4.2 Targeted therapy

4.2.1 Market size and forecast

4.3 Immunotherapy (biologics therapy)

4.3.1 Market size and forecast

4.4 Hormonal therapy

4.4.1 Market size and forecast

4.5 Others

4.5.1 Market size and forecast

Chapter: 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES,2014-2021

5.1 Blood cancer

5.1.1 Market size and forecast

5.2 Breast cancer

5.2.1 Market size and forecast

5.3 Gastrointestinal cancer

5.3.1 Market size and forecast

5.4 Prostate cancer

5.4.1 Market size and forecast

5.5 Respiratory/lung cancer

5.5.1 Market size and forecast

5.6 Skin cancer

5.6.1 Market size and forecast

5.7 Other cancers

5.7.1 Trends in treatment of other cancer types

5.7.2 Market size and forecast

Chapter: 6 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES,2014-2021

6.1 Brazil

6.1.1 Market size and forecast

6.2 Argentina

6.2.1 Market size and forecast

6.3 Nigeria

6.3.1 Market size and forecast

6.4 South Africa

6.4.1 Market size and forecast

6.5 Iraq

6.5.1 Market size and forecast

6.6 Iran

6.6.1 Market size and forecast

6.7 Algeria

6.7.1 Market size and forecast

6.8 Saudi Arabia

6.8.1 Market size and forecast

6.9 Egypt

6.9.1 Market size and forecast

6.10 Other LAMEA countries

6.10.1 Market size and forecast

Chapter: 7 COMPANY PROFILES

7.1 Amgen Inc.

7.1.1 Company overview
7.1.2 Business performance
7.1.3 Operating business segment overview
7.1.4 Key strategies and development
7.1.5 SWOT analysis

7.2 AstraZeneca PLC.

7.2.1 Company overview
7.2.2 Business performance
7.2.3 Key strategies and development
7.2.4 SWOT analysis and strategic conclusions

7.3 Roche Diagnostics

7.3.1 Company overview
7.3.2 Operating business segment overview
7.3.3 Business performance
7.3.4 Key strategies moves and development
7.3.5 SWOT analysis

7.4 GlaxoSmithKline PLC

7.4.1 Company overview
7.4.2 Operating business segment overview
7.4.3 Business performance
7.4.4 Key strategies move and development
7.4.5 SWOT Analysis

7.5 Merck & Company

7.5.1 Company overview
7.5.2 Operating business segment overview
7.5.3 Business performance
7.5.4 Key strategies move and development
7.5.5 SWOT analysis

7.6 Novartis AG

7.6.1 Company overview
7.6.2 Operating business segment overview
7.6.3 Business performance
7.6.4 Key strategies move and development
7.6.5 SWOT analysis

7.7 AbbVie Inc.

7.7.1 Company overview
7.7.2 Business performance
7.7.3 Strategic moves and developments
7.7.4 SWOT analysis

7.8 Sanofi

7.8.1 Company overview
7.8.2 Operating business segment overview
7.8.3 Business performance
7.8.4 Key strategies move and development
7.8.5 SWOT analysis

7.9 EIMC United Pharmaceuticals (EUP)

7.9.1 Company overview
7.9.2 Operating business segment overview
7.9.3 Key strategies move and development
7.9.4 SWOT analysis

7.10 Actavis plc

7.10.1 Company overview
7.10.2 Operating business segment overview
7.10.3 Business performance
7.10.4 Key strategies move and development
7.10.5 SWOT analysis

List of Figures

FIG. 1 TOP FACTORS IMPACTING ANTI-CANCER DRUGS MARKET (2014-2021)
FIG. 2 TOP INVESTMENT POCKETS OF ONCOLOGY/ANTI-CANCER DRUGS MARKET (2014)
FIG. 3 TOP WINNING STRATEGIES FOR GLOBAL CANCER DRUG MARKET (2011-2015)
FIG. 4 TOP WINNING STRATEGIES BY SUBTYPE (2011-2015)
FIG. 5 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 10 LAMEA OTHER DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 11 LAMEA BLOOD CANCER DEATH RATE (PER 100,000), (2014)
FIG. 12 LAMEA BLOOD CANCER MARKET, 2014-2021 ($MILLION)
FIG. 13 LAMEA BREAST CANCER DEATH RATE (PER 100,000), 2014
FIG. 14 LAMEA BREAST CANCER MARKET, 2014-2021 ($MILLION)
FIG. 15 LAMEA GASTROINTESTINAL CANCER DEATH RATE (PER 100,000), 2014
FIG. 16 LAMEA GASTROINTESTINAL CANCER MARKET, 2014-2021 ($MILLION)
FIG. 17 LAMEA PROSTATE CANCER DEATH RATE (PER 100,000), 2014
FIG. 18 LAMEA PROSTATE CANCER MARKET, 2014-2021 ($MILLION)
FIG. 19 LAMEA RESPIRATORY/LUNG CANCER DEATH RATE (PER 100,000), 2014
FIG. 20 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014-2021 ($MILLION)
FIG. 21 LAMEA SKIN CANCER DEATH RATE (PER 100,000), 2014
FIG. 22 LAMEA SKIN CANCER MARKET, 2014-2021 ($MILLION)
FIG. 23 LAMEA OTHER CANCER MARKET, 2014-2021 ($MILLION)
FIG. 24 AMGEN INC. REVENUE BY GEOGRAPHY (2014)
FIG. 25 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2014)
FIG. 26 SWOT ANALYSIS OF AMGEN INC.
FIG. 27 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 28 FINANCIAL REVENUES BY YEAR, 2014 ($MILLION)
FIG. 29 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 30 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2014)
FIG. 31 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 32 GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2014)
FIG. 33 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 34 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 35 MERCK & CO. REVENUE BY GEOGRAPHY (2014)
FIG. 36 SWOT ANALYSIS OF MERCK & COMPANY
FIG. 37 NOVARTIS AG REVENUE BY GEOGRAPHY (2014)
FIG. 38 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 39 SWOT ANALYSIS OF NOVARTIS AG
FIG. 40 NET SALES REVENUES OF ABBVIE BY GEOGRAPHY, 2014 ($MILLION)
FIG. 41 SWOT ANALYSIS OF ABBVIE
FIG. 42 SANOFI REVENUE BY GEOGRAPHIES (2014)
FIG. 43 SANOFI REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 44 SWOT ANALYSIS OF SANOFI
FIG. 45 SWOT ANALYSIS OF EUP
FIG. 46 ACTAVIS CORPORATION REVENUE BY PRODUCT SALES (2014)
FIG. 47 SWOT ANALYSIS OF ACTAVIS PLC

List of Tables

TABLE 1 INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
TABLE 2 LAMEA ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (2012)
TABLE 3 LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
TABLE 4 LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
TABLE 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2014-2021 ($MILLION)
TABLE 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 10 LAMEA OTHER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 11 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES, 2014-2021 ($MILLION)
TABLE 12 LAMEA BLOOD CANCER MARKET, 2014-2021 ($MILLION)
TABLE 13 LAMEA BREAST CANCER MARKET, 2014-2021 ($MILLION)
TABLE 14 LAMEA GASTROINTESTINAL CANCER MARKET, 2014-2021 ($MILLION)
TABLE 15 LAMEA PROSTATE CANCER MARKET, 2014-2021 ($MILLION)
TABLE 16 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014-2021 ($MILLION)
TABLE 17 LAMEA SKIN CANCER MARKET, 2014-2021 ($MILLION)
TABLE 18 LAMEA OTHER CANCER MARKET, 2014-2021 ($MILLION)
TABLE 19 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 20 BRAZIL ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 21 ARGENTINA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 22 NIGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 23 SOUTH AFRICA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 24 IRAQ ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 25 IRAN ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 26 ALGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 27 SAUDI ARABIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 28 EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 29 EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014-2021 ($MILLION)
TABLE 30 AMGEN INC. SNAPSHOT
TABLE 31 ASTRAZENECA SNAPSHOT
TABLE 32 ROCHE DIAGNOSTICS SNAPSHOT
TABLE 33 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 34 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 35 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
TABLE 36 MERCK & COMPANY SNAPSHOT
TABLE 37 MERCK & CO. OPERATING SEGEMENTS
TABLE 38 NOVARTIS AG SNAPSHOT
TABLE 39 NOVARTIS AG OPERATING SEGEMENTS
TABLE 40 ABBVIE INC. SNAPSHOT
TABLE 41 SANOFI SNAPSHOTS
TABLE 42 SANOFI OPERATING SEGEMENTS
TABLE 43 EIMC UNITED PHARMA SNAPSHOTS
TABLE 44 ACTAVIS CORPORATION SNAPSHOTS

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
LAMEA Oncology/Anti-cancer drugs Market- Opportunity Analysis and Industry Forecast, 2014 - 2021

  • Data Pack
  • $2597
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $3497
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $4200
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $5857
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo